Zynerba Pharmaceuticals, Inc. Presenting at the Benzinga Cannabis Capital Conference in Chicago

Chicago, Illinois--(Newsfile Corp. - October 15, 2019) - Zynerba Pharmaceuticals, Inc. ZYNE, will be presenting at the 5th Benzinga Cannabis Capital Conference in Chicago October 22-23 before an audience of well-vetted public and private companies, and an audience of fellow institutional, family office and accredited investors looking for the right opportunities in a crowded and volatile market. Investment opportunities abound.

For more information and/or to register for the conference please visit: https://benzingacannabisconference.com/chicago/?utm_source=newsfile&utm_medium=press_release&utm_campaign=newsfile

Past and future Cannabis Capital Conferences will have heard from luminaries making headlines and disrupting the industry, including:

Bruce Linton | Executive Chairman at Gage Cannabis
Kevin Murphy | Chairman & CEO at Acreage Holdings
Charlie Bachtell | CEO & Co-Founder at Cresco Labs
Kim Rivers | CEO at Trulieve
Hadley Ford | CEO at iAnthus
Brian Schinderle | CFO at Grassroots
Gary Allen | COO at New Frontier Data
Will Stuart | SVP at Harvest One
Josh Genderson | Founder & CEO at Holistic Industries
Rob Kelly | Director of IR at Aurora Cannabis
Peter Miller | CEO at SLANG Worldwide

The 5th Benzinga Cannabis Capital Conference in Chicago October 22-23 is the premier gathering of cannabis entrepreneurs and investors in North America. No other conference offers the level of access and seamlessness of interaction between entrepreneurs building future billion-dollar cannabis enterprises and the investors whose capital will make that happen.

About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. It is also developing ZYN001, a pro-drug of tetrahydrocannabinol. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48606